ALKS240816P27000
- 0.25
- 0.000.00%
Alkermes Newsroom
Despite Shrinking by US$315m in the Past Week, Alkermes (NASDAQ:ALKS) Shareholders Are Still up 19% Over 5 Years
Express News | Alkami Sees Q3 Total Revenue $83.8M-$85.3M Vs $84.78M Est., Sees FY24 Total Revenue $330.5M-$333.5M Vs $331.67M Est
Why Alkermes (ALKS) Is a Top Value Stock for the Long-Term
Strong Buy on Alkermes: Solid Q2 Earnings and Promising Drug Pipeline Drive Positive Outlook
Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating
Express News | Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
Express News | JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $32
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $32 to $38
Alkermes Price Target Raised to $37.00/Share From $35.00 by HC Wainwright & Co.
Alkermes Is Maintained at Neutral by HC Wainwright & Co.
Alkermes Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)
Express News | Alkermes PLC : H.c. Wainwright Raises Target Price to $37 From $35
Express News | Alkermes PLC : Piper Sandler Cuts Target Price to $38 From $39
Express News | Alkermes PLC : JP Morgan Raises Target Price to $32 From $31
Express News | Alkermes PLC : TD Cowen Raises Target Price to $35 From $34
Strong Performance and Clinical Promise Uphold Buy Rating for Alkermes With $32 Target Price
Alkermes Plc (ALKS) Q2 2024 Earnings Call Transcript